Results 241 to 250 of about 231,014 (346)

Low‐Dose vs. Standard Care Iv Human Albumin During Large‐Volume Paracentesis in Patients With Liver Cirrhosis: A Systematic Review

open access: yesLiver International, Volume 46, Issue 5, May 2026.
ABSTRACT Cirrhosis is a global health concern, with ascites being the most prevalent decompensating event. Intravenous (IV) human albumin (HA) is administered during large‐volume paracentesis (LVP) to prevent complications. The standard (6–8 g HA/L ascites) is empirically chosen, potentially leading to overtreatment and added costs.
Kimberly K. I. M. Bot   +3 more
wiley   +1 more source

Albumin Restores Endothelial Cell Mitochondrial Morphology in Patients With Decompensated Cirrhosis

open access: yesLiver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background & Aims Endothelial cell (EC) activation is a critical driver of disease progression in cirrhosis, contributing to acute decompensation (AD) and acute‐on‐chronic liver failure (ACLF). Although human albumin administration improves EC function in cirrhotic patients with hypoalbuminemia, its direct effects on ECs remain unclear.
Susan E. Fischer   +5 more
wiley   +1 more source

Acidic pH Restricts Non‐Tuberculous Mycobacteria Replication

open access: yesMolecular Microbiology, Volume 125, Issue 5, Page 375-388, May 2026.
Different nontuberculous mycobacteria (NTM) species display unique replication profiles in acidic pH in vitro which correlates to their replication within human macrophages. Inhibition of the acidic environments within the macrophage enhances bacterial viability emphasising the role of acidic pH during NTM infections.
Parise K. Lockwood   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy